Amivantamab
Space-filling model of the anti-MET arm of amivantamab (blue) bound to the Sema domain of human MET (puce). PDB: 6wvz | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Epidermal growth factor receptor (EGFR) and MET |
| Clinical data | |
| Trade names | Rybrevant |
| Other names | JNJ-61186372, amivantamab-vmjw |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a621034 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous infusion |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6472H10014N1730O2023S46 |
| Molar mass | 145902.15 g·mol−1 |
Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests.
Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.